Codagenix Inc, a US-based clinical-stage biotechnology company, announced on Wednesday that its novel intranasal COVI-VAC vaccine has indicated promising safety and immunogenicity results in its Phase one dose escalation trial in healthy adults.
Data indicated that the product is likely to block replication of the SARS-CoV-2 virus in the nose. These clinical data, combined with pre-clinical data showing COVI-VAC to be efficacious against a variant of concern, suggest the vaccine has the potential to generate broad immunity against COVID-19. The product is a live-attenuated vaccine candidate produced utilising the company's machine-learning enabled codon deoptimization vaccine design platform that relies on a combination of computational science and synthetic biology to produce systematically attenuated viral vaccines.
The company expects data from the full Phase one trial cohort in late third quarter or fourth quarter of 2021 and will be presenting detailed data from the trial at the IDWeek 2021 Annual Meeting, scheduled from 29 September to 3 October, which will be held virtually.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV